Analysis of a national US database suggests that patients with JIA are at increased risk of serious infection, and that this risk is further increased by treatment with glucocorticoids. By contrast, therapy with methotrexate or TNF inhibitors does not increase this risk, and might even reduce it through steroid-sparing effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Beukelman, T. et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. http://dx.doi.org/10.1002/art.34458.
Lovell, D. J. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342, 763–769 (2000).
Lovell, D. J. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359, 810–820 (2008).
Giannini, E. H. et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 60, 2794–2804 (2009).
Askling, J. & Dixon, W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20, 138–144 (2008).
Batzler, W. U. et al. Cancer in Germany, 2003–2004: incidence and trends, 6th ed. Robert Koch Institute (ed.) and Association of Population-based Cancer Registries in Germany (Robert Koch Institute, Berlin, 2008).
Beukelman, T. et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 64, 1263–1271 (2012).
Horneff, G. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann. Rheum. Dis. 68, 519–525 (2009).
Horneff, G., Bischof, S. & German BIKER Registry collaborative group. Long-term safety of etanercept compared to methotrexate and combinations in children with juvenile idiopathic arthritis—data of the German BIKER-Registry [abstract #260]. Arthritis Rheum. 63 (Suppl. 10), S97 (2011).
Horneff, G. & Semkus, M. Infektionsrisiko bei JIA—Patienten-Daten aus dem Methotrexat und Enbrelregister [abstract in German]. Z. Rheumatol. 68 (Suppl. 1), 135 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has acted as a consultant to Abbott, Pfizer, Novartis and Roche, and has received speaker's honoraria and financial support for scientific analyses from Abbott and Pfizer.
Rights and permissions
About this article
Cite this article
Horneff, G. Biologic therapy and risk of infection in children with JIA. Nat Rev Rheumatol 8, 504–505 (2012). https://doi.org/10.1038/nrrheum.2012.114
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.114
This article is cited by
-
Negative effect of lockdown on juvenile idiopathic arthritis patients
Clinical Rheumatology (2021)